Αποτελέσματα Αναζήτησης
Sharing Alzheimer’s research data with the world. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-center, observational study. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials.
- About
About - ADNI | Alzheimer's Disease Neuroimaging Initiative
- News & Publications
News & Publications - ADNI | Alzheimer's Disease...
- HELP / FAQ
HELP / FAQ - ADNI | Alzheimer's Disease Neuroimaging...
- About
11 Σεπ 2024 · In addition to informing the design of clinical trials, ADNI data have been used extensively for observational research in normal brain aging and dementia to examine correlations between MRI, clinical, genetic, positron emission tomography (PET), and biofluid measures.
31 Δεκ 2021 · In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies.
12 Σεπ 2023 · Section 2 examines how ADNI data have directly contributed to the development of AD therapies, describes important data harmonization efforts, outlines progress in the development of plasma biomarkers for clinical use, and reviews diagnostic and prognostic models.
28 Σεπ 2021 · The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD).
Updated. ADNI has 50+ clinical sites nationwide. See the list of all official ADNI sites here: Official ADNI Sites. Was this article helpful?